Hyams, trial summary    PDF trial summary

A randomised clinical trial investigating the effect of cediranib + fulvestrant versus fulvestrant in


NCT00454805    Invest New Drugs 2013;31:1345-54  

Studied treatment
Control treatment

Group sizes-9 / -9

Blindness Inclusion period
Follow-up duration Centers
Lost to FU geographical localisation
Primary endpoint Design

EndpointX1N1X0N0TE95% CI0,22,01,0

Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, Audeh MW, Alencar VM, Lombard J, Mookerjee B, Xu J, Brown K, Klein P Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs 2013;31:1345-54     [PMID: 23801303]   link to pdf   add to Mendeley  

ClinicalTrial.gov record NCT00454805

Registering number NCT00454805 (see trial on clinicaltrials.gov)
Code Name